Hematologic Cancers

A new web-based application predicts the probability for complete remission (CR) or early death (ED) after chemotherapy in patients aged 60 years and older with acute myeloid leukemia (AML). The tool, developed by the German Acute Myeloid Leukaemia Cooperative Group and the Study Alliance Leukemia Investigators, can help clinicians weigh the option of intensive induction chemotherapy for older, otherwise healthy patients. In addition, the tool requires only standard clinical data and laboratory variables to calculate the risk scores.

CHICAGO—Among patients with chronic myeloid leukemia (CML) in the Evaluating Nilotinib Efficacy and Safety in Clinical Trials-Newly Diagnosed Patients (ENESTnd) study, major molecular response (MMR) rates with nilotinib remain superior to those with imatinib after follow-up extended to a median of 18.5 months.

One third of patients with newly diagnosed, advanced chronic lymphocytic leukemia (CLL) who received the combination of bendamustine and rituximab achieved a complete response, according to researchers from the German CLL Study Group.

Although thrombocytopenia is a common problem in patients with cancer, idiopathic thrombocytopenic purpura (ITP) is relatively rare and is difficult to treat when duration exceeds 6 months. ITP can be either acute (duration ≤6 months) or chronic, can occur in both adults and children, and can be primary or secondary to another disorder, including the malignancy.

Chronic myeloid leukemia (CML) is characterized by the presence of the Philadelphia chromosome (Ph), which is formed by genetic exchange between chromosomes 9 and 22 and codes for the pathogenic tyrosine kinase BCR-ABL.1-3 Historically, therapeutic interventions for CML have included busulfan, hydroxyurea, interferon-a, and stem cell transplantation.4 These therapies vary greatly in tolerability, toxicity, and efficacy.

In the first head-to-head comparison of targeted oral tyrosine kinase inhibitors as initial treatment for early-stage chronic myeloid leukemia (CML), molecular and cytogenetic remissions were more common with nilotinib compared with imatinib, the previous standard for treating early-stage CML, said Giuseppe Saglio, MD.

Page 9 of 9
Results 81 - 86 of 86